Balancing drug risk and benefit: Toward refining the process of FDA decisions affecting patient care

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 815-819

  Schiller, Lawrence R ^a,c   Johnson, David A ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Eastern Virginia School of Medicine   (United States)

^c Digestive Health Associates of Texas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALOSETRON; ANTIDIABETIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; GATIFLOXACIN; PARACETAMOL; PLACEBO; ROFECOXIB; ROSIGLITAZONE; SILDENAFIL; TEGASEROD;

ABDOMINAL PAIN; ANGINA PECTORIS; CHOLECYSTECTOMY; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG MARKETING; DRUG SAFETY; ENTEROPATHY; ERECTILE DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; ISCHEMIC COLITIS; MEDICAL DECISION MAKING; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; STROKE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CARBOLINES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG LABELING; DRUG TOXICITY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK; SEROTONIN AGONISTS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 41849095624     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01818.x     Document Type: Review

References (27)

1. Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance - lack of vigilance, lack of trust. JAMA 2004 292 : 2647 50.
2. Wolfe S. How independent is the FDA? Available at : http://www.pbs.org/ wgbh/pages/frontline/ shows/pres-cription/hazard/independent.html. Accessed November 17, 2007.
3. Avorn J. Paying for drug approvals - who's using whom? N Engl J Med 2007 356 : 1697 700.
4. Deyo RA. Gaps, tensions, and conflicts in the FDA approval process: Implications for clinical practice. J Am Board Fam Pract 2004 17 : 142 9.
5. Zielinski SL. FDA attempting to overcome major roadblocks in monitoring drug safety. JNCI J Natl Cancer Inst 2005 97 : 872 3.
6. Smith SW. Sidelining safety - the FDA's inadequate response to the IOM. N Engl J Med 2007 357 : 960 3.
7. Furberg CD, Levin AA, Gross PA, et al. The FDA and drug safety: A proposal for sweeping changes. Arch Intern Med 2006 166 : 1938 42.
8. Halder SL, Locke GR 3rd., Schleck CD, et al. Natural history of functional gastrointestinal disorders: A 12-year longitudinal population-based study. Gastroenterology 2007 133 : 799 807.
9. TM Tablets, alosetron hydrochloride. Available at : http://www.fda.gov/Cder/drug/infopage/lotronex/ lotronex-qa.htm. Accessed October 30, 2007.
10. Lotronex Tablets (alosetron hydrochloride): Questions and Answers. Available at : http://www.fda.gov/Cder/drug/infopage/lotronex/lotronex-qa_0602. htm. Accessed October 28, 2007.
11. TM (tegaserod maleate) tablets: Prescribing information. Available at : http://www.fda.gov/cder/foi/label/ 2002/ 21200lbl.pdf. Accessed October 28, 2007.
12. Novartis "Dear Healthcare Provider" letter, dated April 26, 2004. Available at : http://www.fda.gov/medwatch/SAFETY/2004/ zelnorm_deardoc_042604.pdf. Accessed October 28, 2007.
13. FDA Announces Discontinued Marketing of GI Drug, Zelnorm, for Safety Reasons. Available at : http://www.fda.gov/bbs/topics/NEWS/2007/NEW01597.html. Accessed October 28, 2007.
14. DA Improvements in Drug Safety Monitoring. Available at : http://www.fda.gov/oc/factsheets/drugsafety.html. Accessed November 17, 2007.
15. Busti AJ, Murillo JR Jr., Cryer B. Tegaserod-induced myocardial infarction: Case report and hypothesis. Pharmacotherapy 2004 24 : 526 31.
16. FDA Permits Restricted Use of Zelnorm for Qualifying Patients. Available at : http://www.fda.gov/bbs/topics/NEWS/2007/NEW01673.html. Accessed October 28, 2007.
17. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999 83 : 29C 34C.
18. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 2000 321 : 1183 7.
19. Larson AM. Acetaminophen hepatotoxicity. Clin Liver Dis 2007 11 : 525 48.
20. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005 42 : 1364 72.
21. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 356 : 2457 71.
22. FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. Available at : http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html. Accessed November 17, 2007.
23. Zhan C, Kaczmarek R, Loyo-Berrios N, et al. Incidence and short-term outcomes of primary and revision hip replacement in the United States. J Bone Joint Surg Am 2007 89 : 526 33.
24. Food and Drug Administration Amendments Act of 2007. Public Law 110-85 - September 27, 2007. 121 Stat. 823-978. Available at : http://thomas.loc.gov/cgi- bin/bdquery/z?d110:h.r.03580 : Accessed January 1, 2008.
25. Swann JP. History of the FDA. Available at : http://www.fda.gov/oc/ history/historyoffda/default.htm. Accessed November 17, 2007.
26. Building a 21st century FDA: Proposals to improve drug safety and innovation. Washington, DC : US Government Printing Office, 2007.
27. Baciu A, Stratton K, Burke SP, eds. The future of drug safety: Promoting and protecting the health of the public. Washington, DC : National Academies Press, 2007.